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INTRODUCTION 
 
 
           Chronic kidney disease is characterized by a decrease in glomerular 
filtration rate and histological evidence of reduction in nephron population. 
The clinical course is typically one of a progressive and unrelenting loss of 
nephron function ultimately leading to end stage renal disease. Kidney 
failure is the most visible aspect of the spectrum, but it represents only a 
minority of the total population affected by kidney disease. 
 
          The time between initial onset of disease and development of terminal 
renal failure may vary considerably not only between different diseases but 
also in different patients with similar disease processes. The progressive 
nature of  CKD and the ensuing ESRD is putting a substantial burden on 
global health resources since all modalities of treatment are expensive.  
 
         There are multiple causes of kidney injury that lead to the final 
common pathway of ESRD, and this syndrome is characterized by 
hypertension, anemia, renal bone disease, nutritional impairment, 
neuropathy, impaired quality of life, and reduced life expectancy. Increasing 
evidence acquired in the past decades indicates that the adverse outcomes of 
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CKD such as renal failure, cardiovascular disease, and premature death  can 
be prevented or delayed by early detection of CKD. Earlier stages of CKD 
can be detected through laboratory testing only. Treatment of earlier stages 
of chronic kidney disease, as well as initiation of treatment of cardiovascular 
risk factors at early stages of CKD should be effective in reducing the rate of 
progression of CKD to ESRD.  
 
           Unfortunately, despite the evident importance of CKD there is limited 
data on its epidemiology within the general population, especially from 
developing countries like India. Two community-based studies have shown 
a prevalence of chronic renal failure of 0.16%1 and 0.79%2. Renal failure 
registry data is unlikely to be representative of the broader spectrum of CKD. 
There is a wide variability both within and between countries in the 
occurrence, clinical characteristics and outcomes of patients with kidney 
failure and there have been substantial changes over time. Only 3% to 5% of  
all patients with ESRD in India get some form of renal replacement therapy3. 
Thus, planning for prevention of CKD on a long-term basis is the only 
practical solution for India. 
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                This study was taken up to highlight the epidemiological 
characteristics, clinical presentation, etiology, complications and outcome of 
patients who presented with CKD to a Government tertiary care hospital.  
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AIMS AND OBJECTIVES 
 
           
         To study  
       
 
1. the demographic and clinical profile of patients with Chronic      
kidney disease. 
 
2. the etiological diagnosis, risk factors and complications of patients      
with Chronic kidney disease. 
       
3. the treatment options given to patients with Chronic kidney       
disease. 
 
4.  the correlation of risk factors and complications with respect to                   
staging of Chronic kidney disease.  
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REVIEW OF LITERATURE 
 
 
CHRONIC KIDNEY DISEASE   
       Chronic kidney disease represents the entire spectrum of disease that 
occurs following the initiation of kidney damage. The introduction of a 
formal definition for CKD has enabled standardize current medical 
communication, facilitate appropriate population based screening, and 
encourage timely prevention and treatment of kidney disease. 
 
DEFINITION4 
1. Kidney damage for > 3 months, as defined by structural or functional       
abnormalities of the kidney, with or without decreased GFR, manifest      
by either     
• Pathological abnormalities; or     
• Markers of kidney damage, including abnormalities in the                
composition of the blood or urine, or abnormalities in         
imaging     test. 
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2. GFR < 60 mL / min / 1.73 m2 for > 3 months, with or without kidney      
damage. 
 
            The GFR is considered the best measure of overall kidney function. 
A GFR level below 60 mL / minute / 1.73 m2 represents loss of one half or 
more of the adult level of normal kidney function. Normal GFR varies 
according to patient age, sex, and body size. The MDRD formula is a better 
estimate of GFR than those derived from 24-h urinary creatinine clearance or 
the Cockcroft-Gault formula. The abbreviated MDRD formula requires age, 
gender, race, and serum creatinine. 
 
The Abbreviated MDRD Formula5 
 
eGFR = 186 × ([SCR/88.4]–1.154) × (age) –0.203 × (0.742 if female) × (1.210 if            
African-American) 
where  
eGFR = estimated glomerular filtration rate (mL/min/1.73m2),  
SCR = serum creatinine concentration (µmol/L), and age is expressed in           
years                              
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AGE 
           In young adults, the normal GFR is approximately 120 to 130 mL 
/minute / 1.73 m2 and declines with age.6  A decreased GFR in an elderly 
patient appears to be an independent predictor of adverse outcomes such as 
mortality and cardiovascular disease7,8. Because of the age-related decline in 
GFR, the prevalence of chronic kidney disease increases with age; 
approximately 17 percent of persons older than 60 years have an estimated 
GFR of less than 60 mL / minute / 1.73 m2. 
 
GENDER 
              Male gender has been recognized as an important factor in the 
development of CKD9. Gender-based genetic variability has been linked to 
differences in BP in both black10 and white individuals11. Males may be 
more susceptible to CKD, which would explain the higher proportion in 
renal replacement therapy programmes. In contrast to testosterone, 12,13 
estrogens may attenuate CKD progression by lowering the cardiovascular 
stress response to adrenergic stimuli14.  
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            Chronic kidney disease is a national public health problem  beset by 
inequities in incidence, prevalence, and complications across race/ethnicity, 
and socioeconomic status.  
 
SOCIOECONOMIC STATUS 
           In U.S, geographic analyses have revealed community-level  poverty 
was strongly associated with higher ESRD incidence but was a more 
powerful predictor for black than for white individuals.15  Racially divided 
communities may share low-income status but often differ in wealth, 
community assets, exposure to heavy metals or excess ambient air 
particulate matter, and other variables that may influence CKD-related 
outcomes.16 
 
RACE 
             Racial factors also have a role in the susceptibility to CKD as shown 
by high prevalence of CKD related to hypertension, diabetes, or both, among 
Africans and native Americans in USA as well as Afro-Caribbean and Asian 
individuals in UK.17 In U.S, ESRD rates in minorities ranged from 1.5 to 4 
times those of age-adjusted counterparts, despite similar rates for the early 
stages of CKD.18 
 9
      
STAGING OF CHRONIC KIDNEY DISEASE 
           As patients pass through the continuum of progressive kidney  
damage, there are predictable complications, such as the development of 
anemia, and an elevated parathormone levels and predictable management 
issues such as dialysis access preparation. The NKF/ KDOQI staging 
system4 for CKD was developed to address this need.  
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Stage Description 
GFR (mL 
per minute 
per 1.73 
m2) 
U.S. 
prevalence, 
number of 
affected 
patients (%) Action plan 
- At increased 
risk for 
chronic 
kidney 
disease 
> 60 (with 
risk factors 
for chronic 
kidney 
disease) 
 Screening, reduction of 
risk factors for chronic 
kidney disease 
1 Kidney 
damage with 
normal or 
elevated GFR 
>= 90 5.9 million 
(3.3) 
Diagnosis and treatment, 
treatment of comorbid 
conditions, interventions 
to slow disease 
progression, reduction of 
risk factors for 
cardiovascular disease 
2 Kidney 
damage with 
mildly 
decreased 
GFR 
60 to 89 5.3 million 
(3.0) 
Estimation of disease 
progression 
3 Moderately 
decreased 
GFR 
30 to 59 7.6 million 
(4.3) 
Evaluation and treatment 
of disease complications 
4 Severely 
decreased 
GFR 
15 to 29 400,000 (0.2) Preparation for kidney 
replacement therapy 
(dialysis, transplantation) 
5  Kidney 
failure  
< 15 (or 
dialysis)  
300,000 (0.1) Kidney replacement 
therapy if uremia is 
present  
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EARLY KIDNEY DISEASE – STAGES 1 AND 2 
 
            For stages 1 and 2, kidney damage is detected by a ratio of greater 
than 17 mg of albumin to 1 g of creatinine in men or greater than 25 mg of 
albumin to 1 g of creatinine in women on two untimed (spot) urine tests. The 
key issue in this group of patients becomes identification of whether renal 
function is likely to decline. The patients who at significant risk of 
progressing19 include proteinuria >1 g/day20, poorly controlled blood 
pressure, certain underlying diagnoses like diabetic nephropathy, should be 
promptly evaluated and managed to decrease the risk of progression to End 
Stage Renal Disease (ESRD). 
 
STAGE 3 CKD  
          Patients with stage 3 CKD have significant renal impairment and are 
probably the very group in whom renal failure is poorly recognised.21 In 
patients with progressive renal failure, it is desirable to institute treatment to 
delay the need for dialysis. There is good evidence to support the efficacy of 
such measures in proteinuric patients.22,23 The natural history of renal 
impairment in non-proteinuric patients, however, is not well-defined, and 
will depend at least in part on the underlying cause of renal damage. The 
large majority of these patients will not progress sufficiently to require 
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dialysis.24 However, patients with stage 3 CKD have substantially increased 
cardiovascular risk compared to patients with better renal function, with a 
43–100% increased risk of cardiovascular events25 and most of them will die 
as a result of cardiovascular disease before ever needing dialysis.26 Increased 
cardiovascular risk appears to start increasing as GFR declines below 75 
l/min/1.73 m2. 27 Management revolves around vigorous treatment of  
hypertension, particularly with blockade of the renin-angiotensin system, to 
a blood pressure <130/80 mmHg (<125/75 mmHg if proteinuria >1 g/day is 
present), and treatment of other cardiovascular risk factors. 
 
STAGE 4 AND 5 
               These patients have marked disruption to normal physiology, 
causing complications such as renal anemia and renal osteodystrophy that 
require specialist management. These are also the stages at which 
preparations for dialysis and transplantation are required. Late referral of 
patients with advanced renal failure to nephrologists compromises the 
preparations for dialysis and subsequent survival of those patients28 and is 
more costly than timely referral.29 Even patients who are unsuitable for 
dialysis (or are unwilling to undergo it) will benefit from management of 
their anemia and bone disease, and potentially from palliative care.30    
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         Kidney failure is defined as a GFR below 15 mL / minute / 1.73 m2, 
usually accompanied by signs and symptoms of uremia, or as the need for 
initiation of kidney replacement therapy for management of the 
complications of a decreased GFR. In the United States, approximately 98 
percent of patients begin dialysis when their GFR falls below 15 mL /minute 
/ 1.73 m2. 31 
          The number of patients with end stage renal disease is growing 
worldwide. About 20-30 patients have some degree of renal dysfunction for 
each patient who needs renal replacement treatment.32  Diabetes and 
hypertension are the two most common causes of end stage renal disease and 
are associated with a high risk of death from cardiovascular disease.33  Early 
detection and treatment often can prevent or delay some of these adverse 
outcomes.34  However, opportunities for prevention may be lost because 
chronic kidney disease is not diagnosed or is treated insufficiently35,36 due to 
lack of uniform application of simple tests for the detection and evaluation 
of the disease.37  
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RISK FACTORS FOR CHRONIC KIDNEY DISEASE AND ITS  
OUTCOMES4 
 
 
Type Definition Examples 
Susceptibility 
factors 
Factors that increase 
susceptibility to kidney 
damage 
Older age, family history of 
chronic kidney disease, reduction 
in kidney mass, low birth weight, 
racial or ethnic minority status, 
low income or educational level 
Initiation 
factors 
Factors that directly 
initiate kidney damage 
Diabetes mellitus, high blood 
pressure, autoimmune diseases, 
systemic infections, urinary tract 
infections, urinary stones, 
obstruction of lower urinary 
tract, drug toxicity 
Progression 
factors 
Factors that cause 
worsening kidney 
damage and faster 
decline in kidney 
function after kidney 
damage has started 
Higher level of proteinuria, 
higher blood pressure level, poor 
glycemic control in diabetes, 
smoking 
End-stage 
factors 
Factors that increase 
morbidity and mortality 
in kidney failure 
Infection, cardiovascular factors, 
anemia, low serum albumin 
level, late referral for dialysis 
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ETIOLOGY 
 
         Diagnosis of chronic kidney disease traditionally is based on pathology 
and etiology, broadly divided into diabetic, glomerular, vascular, 
tubulointerstitial, and cystic kidney diseases. 
 
 
ETIOLOGY 
 
WHITES* 
 
BLACKS* 
ASIAN 
AMERICANS* 
 
INDIANS** 
 
Diabetes mellitus 43.5% 42.1% 42.6% 27.4% 
 
Hypertension 24% 32.9% 23.5% 15.5% 
 
Glomerulonephritis 12% 10.4% 17.3% 19.3% 
 
Interstitial 
nephritis 4.8% 2.0% 2.9% 8.6% 
 
Cystic 
disease/hereditary 3.8% 1.5% 2.2% 3.9% 
 
Miscellaneous 6.2% 6.0% 2.4% 12.1% 
 
Unknown 5.7% 5.1% 5.5% 13.2% 
 
TOTAL 100% 100% 100% 100% 
 
*USRDS Data 2001 
 
**All India CKD Registry of the Indian Society of Nephrology 
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       In developing countries, evidence is lacking regarding the etiology of 
CKD because of poor data collection. Infectious diseases and infection 
related chronic glomerulonephritis form a major cause of CKD and end 
stage renal disease.38 In spite of this, it is believed that diabetes and 
hypertension are the leading causes of CKD in India. 
 
RISK FACTORS FOR CKD 
DIABETES 
               In the United States, diabetic kidney disease is the most common 
cause of kidney failure. It accounts for nearly 45% of all new cases of ESRD 
starting renal replacement therapy between 1996 and 2006. Its earliest 
manifestation is microalbuminuria with a normal or elevated GFR. Effective 
control of blood glucose and blood pressure reduces the renal complications 
of diabetes. Meticulous control of blood glucose has been conclusively 
shown to reduce the development of microalbuminuria by 35% in type 1 
diabetes (Diabetes Control and Complications Trial)39 and in type 2 diabetes 
(United Kingdom Prospective Diabetes Study).40 Other studies have 
indicated that glycemic control can reduce the progression of diabetic renal 
disease.41 
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Adequate control of blood pressure with a variety of antihypertensive 
agents, including angiotensin converting enzyme inhibitors, has been shown 
to delay the progression of albuminuria in both type 1 and type 2 
diabetes42,43 Recently, angiotensin receptor blockers have been shown to 
have renoprotective effects in both early and late nephropathy due to type 2 
diabetes.44  
  
HYPERTENSION  
          Hypertension is the second most common cause of ESRD in the 
United States, accounting for 23% of incident ESRD patients between 1996 
and 2000.45 Hypertension is a well established cause, a common 
complication, and an important risk factor for progression of renal disease. 
Controlling hypertension is the most important intervention to slow the 
progression of renal disease. Angiotensin converting enzyme inhibitors are 
particularly effective in slowing progression of renal insufficiency in 
patients with and without diabetes.46 Angiotensin receptor blockers have a 
renoprotective effect in diabetic nephropathy, independent of reduction in 
blood pressure.50  
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              Non-dihydropyridine calcium channel blockers also have a role in 
retarding progression of renal insufficiency in patients with type 2 diabetes. 
Early detection and effective treatment of hypertension to target levels is 
essential. Hypertension is the most common complication of CKD. 
Hypertension is more difficult to control in patients with CKD. In one study, 
only 11% of CKD patients had BP levels lower than 130/85 mm Hg; 27% of 
these patients had a BP that was lower than 140/90 mm Hg; and 62% of 
them had a BP that was higher than 140/90 mm Hg.48 
  
PROTEINURIA 
            Proteinuria, previously considered a marker of renal disease, is itself 
pathogenic and is the single best predictor of disease progression. Reducing 
urinary protein excretion slows the progressive decline in renal function in 
both diabetic and non-diabetic kidney disease. Angiotensin blockade with 
angiotensin converting enzyme inhibitors or angiotensin receptor blockers is 
more effective at comparable levels of blood pressure control than 
conventional antihypertensive agents in reducing proteinuria, decline in 
glomerular filtration rate, and progression to end stage renal disease.49  
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DYSLIPIDEMIA 
             Lipid abnormalities may be evident with only mild renal impairment 
and contribute to progression of chronic renal disease and increased 
cardiovascular morbidity and mortality. Hydroxymethyl glutaryl coenzyme  
A reductase inhibitors (statins) decreased proteinuria and preserved 
glomerular filtration rate in patients with renal disease, an effect not entirely 
explained by reduction in blood cholesterol.50 
 
HYPERURICEMIA 
            A link between hyperuricemia and the development of systemic 
hypertension, cardiovascular disease, and renal disease has also been 
postulated.51 
 
OBESITY  
             Obesity has been associated with initiation and progression of 
glomerulonephritis.52,53  Among NHANES III participants, the risk of either 
incident ESRD or kidney disease related death was independently a body 
mass index greater than or equal to 35 kg/m2.54 Obese people were more 
likely to have a decrease in estimated GFR.55 
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CIGARETTE SMOKING 
              Cigarette smoking has been implicated in initiation as well as 
progression of CKD. The incidence of ESRD was increased by 5.9 times 
among heavy smokers (>15 pack years).56 In another study, heavy smokers 
(> 20 pack years) had a risk of developing albuminuria three times that of 
non-smokers.57 Smoking cessation alone may reduce the risk of disease 
progression by 30% in patients with type 2 diabetes.58 Smoking increases the 
risk of cardiovascular events in men with kidney disease.59 
 
ALCOHOL  
            Regular and heavy (> two drinks daily) consumption of alcohol 
might also increase the risk of ESRD.60 
 
ANALGESIC ABUSE 
            Consumption of analgesics, especially paracetamol and NSAIDs 
have been linked with a higher risk of developing CKD.61 
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COMPLICATIONS OF CHRONIC KIDNEY DISEASE 
 
ANEMIA 
             Anemia of chronic renal disease begins when the glomerular 
filtration rate falls below 30-35% of normal and is normochromic and 
normocytic. This is primarily caused by decreased production of  
erythropoietin by the failing kidney,62 other factors contributing to anemia 
include inhibitors of erythropoiesis, shortened RBC life span, platelet 
dysfunction, decreased iron intake, and secondary hyperparathyroidism. 
Anemia is an independent predictor of mortality and has also been 
associated with increased morbidity in CKD. Correction of anemia improves 
the quality of life, cognitive and sexual function, reversal of ST-T changes 
on ECG, and reversal as well as prevention of left ventricular hypertrophy, 
reduces the frequency of heart failure and hospitalization among patients 
receiving dialysis.63,64 Whether anemia accelerates the progression of renal 
disease is controversial. Treatment of anemia with recombinant human 
erythropoietin may slow progression of chronic renal disease.65 
 
       Both National Kidney Foundation and European best practice guidelines 
recommend evaluation of anemia when hemoglobin is <11 g/dl and 
consideration of recombinant human erythropoietin to maintain a target 
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hemoglobin of >11 g/dl.66 But when The United States Normal Hematocrit 
study evaluated 1,233 hemodialysis patients with clinical evidence of 
congestive heart failure or ischemic heart disease, the risk ratio (for death 
and non-fatal myocardial infarction) was 1.3 for the normal hematocrit 
group as compared to the low hematocrit group.67 
 
HYPERPHOSPHATEMIA AND HYPERPARATHYROIDISM 
             Hyperparathyroidism is one of the earliest manifestations of 
impaired renal function,68 found in patients with a glomerular filtration rate 
of 60 ml/min.69 Parathormone is a major uremic toxin that causes bone 
disease, metastatic calcification, pruritus, encephalopathy, peripheral 
neuropathy, anemia, sexual dysfunction, and hyperlipidemia. Control of  
serum phosphate levels is a central goal in the management of chronic renal 
failure. Precipitation of calcium phosphate in renal tissue begins early, may 
influence the rate of progression of renal disease, and is closely related to 
hyperphosphatemia and calcium phosphate product. This plays a pivotal role 
in vascular calcification, CVD, calciphylaxis, and death. A calcium-
phosphorus product greater than 72 mg2/dL70 is associated with a 34 percent  
increase in mortality as compared to a product of 45 to 52 mg2/dL.71  
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             Elevated serum phosphate is an independent risk factor for death due 
to cardiovascular events by enhancing vascular calcification of  
atherosclerotic plaques and increased myocardial calcification. Patients with 
serum phosphate levels greater than 6.5 mg/dL have a 41% greater risk of  
death resulting from coronary artery disease and a 20% greater risk of 
sudden death as compared with patients with serum phosphate levels 
between 2.4 and 6.5 mg/dL after adjusting for several known mortality risk 
factors.68 
  
MALNUTRITION 
                The prevalence of hypoalbuminemia is high among patients 
beginning dialysis, is of multifactorial origin, and is associated with poor 
outcome. Hypoalbuminemia may be a reflection of chronic inflammation 
rather than of nutrition in itself. Spontaneous intake of protein begins to 
decrease when the glomerular filtration rate falls below 50 ml/min. 
Progressive decline in renal function causes decreased appetite, thereby 
increasing the risk of malnutrition. 
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CARDIOVASCULAR DISEASE 
               The prevalence, incidence, and prognosis of clinical cardiovascular 
disease in renal failure is not known with precision, but it begins early and is 
independently associated with increased cardiovascular and all cause 
mortality.  
 
RISK FACTORS ASSOCIATED WITH CARDIAC DISEASE73 
Traditional 
Age                                               Gender                            Race 
Smoking                                       Diabetes                          Body mass index 
Hypertension                                Dyslipidemia                  Left ventricular    
                                                                                             hypertrophy 
 
CKD-related risk factors 
Anemia                                  Calcium phosphate        Cytokines 
Electrolyte imbalance            Malnutrition                  Hypoalbuminemia 
Inflammation                         C-reactive protein         Endothelial activation                 
Prothrombotic factors            Increased oxidative stress  
Hyperhomocysteinemia        Advanced glycation end-products 
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Therapy-related 
Dialysis                                      Transplant– Acute rejection                                                      
                                                                    – Immunosuppressives 
 
             Cardiac disease, including left ventricular structural and functional 
disorders, is an important preventable and potentially treatable comorbidity 
of early kidney disease.74 Patients with chronic kidney disease should be 
considered in the "highest risk" group for subsequent cardiovascular events75 
and appropriately managed.79 
 
TREATMENT PRINCIPLES 
 
1. Hypertension is both a cause and a complication of chronic kidney               
disease and should be carefully controlled in all patients  
2. Treatment of co morbid conditions, interventions to slow progression  
     of kidney disease, and measures to reduce the risk for CVD should  
     begin during stage 1 and stage 2.  
3. Evaluation and treatment of other complications of decreased GFR,  
     such as anemia, malnutrition, bone disease, neuropathy, and  
     decreased quality of life, should be undertaken during stage 3, as the  
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     prevalence of these complications begins to rise when GFR declines    
     to less than 60 mL/min per 1.73 m2.  
4. Preparation for kidney replacement therapy should begin during    
     stage 4, well before the stage of kidney failure.  
5. Initiation of dialysis and transplantation is triggered by the onset of  
     uremic symptoms. Preparations for these treatments should begin  
        when GFR declines to less than 15 mL/min per 1.73 m2 (stage 5). 
 
SIGNS AND SYMPTOMS IN CHRONIC  KIDNEY DISEASE 
General 
Fatigue and malaise                         Edema (peripheral and periorbital) 
Decreased urine output in late stages 
Cardiac  
Hypertension                                                    Dyspnea 
Heart failure                                                     Fluid overload 
Markers of accelerated atherosclerosis            Pericarditis  
Gastrointestinal  
Anorexia                                                        Nausea  
Vomiting                                                       Bleeding 
Dysguesia                                                      Constipation  
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Neuromuscular 
Restless legs syndrome                                 Muscle cramps 
Impaired cognition                                        Seizures 
Peripheral neuropathy                                   Loss of lean body mass 
Bone pain 
Dermal  
Pallor                                                              Pruritus 
Ecchymosis 
Ophthalmologic 
Fundoscopic changes of hypertension and diabetes 
 
 
PREVIOUS RELATED STUDIES 
 
          CKD Registry of India data collected from many centres all over India, 
25714 CKD patients were studied with a mean age of 48.3±16.6years, 
68.9% males, 2.2 percent were in stage 1, 4.4 percent in stage 2, 19.1 percent 
in stage3, 24 percent in stage 4 and 50.3 percent in stage 5, irrespective of 
educational status or family income. Diabetic nephropathy was the most 
common etiology (30.3%), CGN (15.8%) and hypertensive nephrosclerosis 
(14.5%) the next common diagnoses. Majority (76.9%) were managed 
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conservatively, dialysis with MHD in 17.9%, CAPD in 2.7% and 
transplantation in 2.5%. Cardiovascular disease increased from 0.6% in 
stage 1 to 51% in stage 5 with IHD being the commonest (44.2%) and LVH 
in 31.6%. Anemia (hemoglobin <11g/dl) was present in 67.4% in stage 1 
which increased to 98.7% in stage 5. 
 
                In NHANES Study77 1999-2004, the total crude CKD prevalence 
estimate for adults aged >20 years in the United States was 16.8%. [stage 
1,5.7%; stage 2, 5.4%; stage 3, 5.4%; stages 4/5, 0.4%].  39.4% were >60 
years, 12.6% aged 40-59 years and 8.5% were in the age group 20-39 years. 
CKD (all stages) was more prevalent among persons with less than a high 
school education (22.1%) than persons with at least a high school education 
(15.7%). CKD prevalence also was greater among persons with diabetes 
(40.2% versus 15.4%), with cardiovascular disease (28.2% versus 15.4%), 
with hypertension (24.6% versus 12.5%), among non-Hispanic blacks 
(19.9%) and Mexican Americans (18.7%) than among non-Hispanic whites 
(16.1%). This racial/ethnic disparity was most pronounced among 
participants with stage 1 CKD.   
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                 In an etiopathological study done over a 6 year period in CMC 
Vellore78 on 457 CKD patients in stage 4 and stage 5, excluding diabetic 
nephropathy, with a mean age of 38.2±14.5years, 62% males, the most 
common etiology of CKD by renal biopsy study was glomerular disease 322 
(70.5%), followed by interstitial nephritis 55 (12%), benign 
arterionephrosclerosis 30 (6.6%), metabolic nephropathies 28 (6.1%), end-
stage parenchymal disease 12 (2.6%) and other 10 (2.2%). There was no 
significant difference in the incidence of etiologies among patients with 
CKD stage 4 and stage 5. 
 
               In a cross-sectional study done over 2 years on 230 CKD patients 
(160 males, 70 females), with mean age of 53.55 years in a tertiary care 
centre in Chennai,79 51% of the patients in CKD stages I, II and III had 
anemia (Hb<11gm/dl), 16%in the group had elevated PTH, 79% of male 
patients and 71% of female patients had LVH. In Stage IV CKD, 55% of the 
patients had anemia, 25% of the patients had elevated PTH, 74% of male 
patients and 100% of female patients had LVH. In stage V CKD, 76% of the  
patients had anemia, 31% of the patients had elevated PTH, 77% of male 
patients and 96% of female patients had LVH. In all five stages, 78% of  
male patients and 71% of female patients with elevated PTH had LVH, 81% 
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of male patients and 90% of female patients with anemia had LVH. 
Systemic hypertension was present in 69% of the patients. Of the male 
patients, 82% with Hb < 7 gm/dl, 80% with Hb between 7.1-11 gm/dl and 
68% with Hb > 11 gm/dl had LVH. Similarly among female patients, 91% 
with Hb < 7gm/dl, 89% with Hb between 7.1-11 gm/ dl, and 63% with Hb 
>11 gm/dl had LVH.  
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MATERIALS AND METHODS 
 
SETTING 
 Patients attending the Nephrology department, Madras Medical College  
and Government General Hospital,  Chennai  
 
COLLABORATION DEPARTMENTS 
Institute of Internal Medicine 
Department of Nephrology 
 
ETHICAL APPROVAL 
Institute Ethical Committee approved the study 
 
STUDY DESIGN 
Single Center 
Non randomized cross sectional study 
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STUDY PERIOD 
Study was conducted between January 2008 and June 2008 for a period of 6  
months 
 
SAMPLE SIZE 
In the study period of 6 months among the patients seen under the 
Department of Nephrology, after applying inclusion criteria, 333 patients 
were included in this study.  
 
SELECTION OF STUDY SUBJECTS 
The patients who were diagnosed as chronic kidney disease based on the 
National Kidney Foundation definition. 
 
INCLUSION CRITERIA 
The patients who were newly diagnosed as chronic kidney disease   
 
CONSENT 
All participates gave informed consent. 
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METHODOLOGY 
Patients who were included in the study were evaluated by history taking,  
clinical examination and laboratory investigations and the information was 
entered based on the proforma prepared.  
 
STATISTICAL ANALYSIS 
Excel and SPSS 12 were used for data analysis 
 
CONFLICT OF INTEREST 
None 
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RESULTS AND OBSERVATIONS 
 
 
POPULATION CHARACTERISTICS 
Among the 333 patients included in the study, 217 (65.17%) were males and 
116 (34.83%) were females. Majority (275; 82.59%) of the patients in the 
study were between 21 – 60 yrs of age. 
 
TABLE1. AGE AND SEX DISTRIBUTION OF THE STUDY                 
                 POPULATION 
 
 
AGE  
 
GROUP 
 
TOTAL 
 
PERCENTAGE
 
MALE 
 
FEMALE 
 
≤ 20 Yrs 22 6.61 11 11 
 
21-40 Yrs 117 35.14 63 54 
 
40-60 Yrs 158 47.45 119 39 
 
>60 Yrs 36 10.81 24 12 
 
 333 100.00 217 116 
 
 
 
AGE RANGE 
 
MEAN 
 
SD 
 
8- 80 Yrs 
 
43.81 
 
14.87 
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EDUCATIONAL STATUS 
In our study, 132 (39.64%) patients were illiterate, 149(44.74%) had primary 
education, 43 (12.91%) had secondary education, while the rest, 9 (2.7%) 
were graduates. 
 
SOCIO ECONOMIC STATUS 
Out of the 333, 86.48% patients in the study had family income of < Rs 
5000, 13.51% between Rs 5000 and 20000, while none of the patients had a 
family income above Rs 20000. 
 
BASIC ETIOLOGICAL DIAGNOSIS  
           Chronic glomerulonephritis was the most common diagnosis – 170 
(51.05%), followed by Diabetic nephropathy - 73 (21.92%), Hypertensive 
nephrosclerosis - 26 (7.81%) Chronic tubulointerstitial disease - 16 (4.80%), 
ADPKD - 8 (2.40%), Obstructive uropathy - 4 (1.20%), Renovascular 
disease -2,  acute cortical necrosis -1. In 33 (9.91%) patients, diagnosis 
could not be established with the available noninvasive investigations and 
were classified as having undetermined etiology. 
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TABLE 2.  ETIOLOGICAL DIAGNOSIS  
 
 
BASIC  
 
DIAGNOSIS 
TOTAL PERCENTAGE MALE FEMALE 
 
CGN 170 51.05 110 60 
 
DIAB NEPH   73 21.92 47 26 
 
HTN NEPH 26 7.81 19 7 
 
TID 16 4.80 10 6 
 
ADPKD 8 2.40 6 2 
 
OBST UROP 4 1.20 4 0 
 
MISC 3 0.90 1 2 
 
UNDETER 33 9.91 20 13 
 
 333 100.00 217 116 
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TABLE 3. AGEWISE DISTRIBUTION OF CAUSES OF CKD 
 
 
 
BASIC 
 
DIAGNOSIS 
≤20 yrs 21-40 yrs 41-60 yrs >60 yrs 
 
CGN 14 88 60 8 
 
DIAB NEPH 0 6 55 12 
 
HTN NEPH 0 3 20 3 
 
TID 5 4 3 4 
 
ADPKD 0 2 6 0 
 
OBST UROP 0 1 3 0 
 
MISC 1 1 1 0 
 
UNDETER 2 12 10 9 
 
 22 117 158 36 
 
 
Maximum number of Diabetic nephropathy was in the 5th and 6th decades 
while Chronic glomerulonephritis was more common in the 3rd and 4th 
decades. 
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DIABETES MELLITUS IN THE STUDY POPULATION 
 
            
 Out of 333 patients in our study, 80 (24.02%) had diabetes mellitus, of   
which 50 were males and 30 females. 
 
TABLE 4. AGEWISE AND DURATIONWISE DISTRIBUTION 
OF DIABETES MELLITUS IN CKD 
 
AGE 
 
GROUP 
Number DURATION  
 
OF DM 
Number 
 
≤20yrs 0 <5yrs 19 
 
21-40yrs 6 5-10yrs 32 
 
41-60yrs 58 10-15yrs 17 
 
>60yrs 16 15-20yrs 9 
 
TOTAL 80 
 
>20yrs 3 
    
 
 
Of the 80 diabetics, 52 (65%) were on oral hypoglycemic agents only, 18 
(22.5%) were on insulin only while 10 (12.5%) were on combination 
treatment. 
 
 39
HYPERTENSION IN THE STUDY POPULATION 
                In our study 282 (84.68%) patients had hypertension, of which, 
176 were males and 106 females. Only in 26 (7.81%) the cause of CKD was  
hypertensive nephrosclerosis. 
 
TABLE5. AGEWISE AND DURATIONWISE DISTRIBUTION 
OF HYPERTENSION IN CKD 
 
AGE 
 
GROUP 
Number DURATION  
 
OF HTN 
Number 
 
     ≤20yrs 14 <5yrs 226 
 
21-40yrs 103 5-10yrs 38 
 
41-60yrs 137 10-15yrs 15 
 
>60yrs 28 15yrs 3 
 
Total 282 
 
Total 282 
 
   
             While 29 (10.28%) out of the 282 were not on any treatment for 
hypertension, 94 (33.33%) were on 1 drug, 146 (51.77%) on 2 drugs and 13 
(4.61%) were on 3 anti-hypertensive drugs. In the study, 60 (18.02%) 
patients were on ACE inhibitors or ARBs. 
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CARDIOVASCULAR DISEASE IN THE STUDY 
POPULATION 
 
                Among the 333 patients included in the study, 167 (50.15%) were 
found to have some form of cardiovascular disease, of which 120(71.86%) 
were males and 47(28.14%) were females.  
            Among the patients with cardiovascular disease, 83.93% had left 
ventricular hypertrophy, 16.17% had ischemic heart disease and 7.78% had 
congestive heart failure. 8 patients had ischemic heart disease or congestive 
heart failure or both in addition to left ventricular hypertrophy. 
                Diabetes mellitus was present in 49 (29.3%) and 159 (95.2%) had 
hypertension. 
TABLE6. AGEWISE DISTRIBUTION OF CARDIOVASCULAR 
DISEASE IN CKD 
 
 
AGE GROUP 
 
NUMBER 
 
PERCENTAGE 
 
≤ 20yrs 
 
6 
 
3.59 
 
21-40yrs 
 
53 
 
31.74 
 
41-60yrs 
 
89 
 
53.29 
 
>60yrs 
 
19 
 
11.38 
 
Total 
 
167 
 
100 
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TABLE7. FAMILY HISTORY OF PREDISPOSING FACTORS   
                  
                 FOR CKD 
 
 
 
 
F/H DM F/H HTN F/H CKD F/H CVD 
 
      Yes 29 43 4 0 
 
No 304 290 329 333 
 
                Of the 4 patients with family history of CKD, 2 were diagnosed to 
have ADPKD. Chronic glomerulonephritis was the diagnosis in the other 2 
patients.  
 
 
TABLE8. HABITS IN THE STUDY POPULATION 
 
 
 
HABIT 
NUMBER PERCENTAGE MALE FEMALE 
 
Smoking 109 32.73 106 3 
 
Chewing  
Tobacco 23 25.86 12 11 
 
Alcohol 86 6.91 86 0 
 
NSAID use 17 5.10 10 7 
 
Herbominerals 15 4.50 12 3 
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PRESENTING SYMPTOMS OF THE STUDY POPULATION 
 
         Of the 333 patients, 242 (72.67%) had symptoms suggestive of volume 
overload state like pedal edema, puffiness of face, abdominal distension. 
Oliguria was present in 231 (69.36%) and 252 (75.68%) had dyspnea. 
Gastrointestinal  symptoms like nausea, vomiting, decreased appetite were 
present in 223 (66.97%), while neuromuscular symptoms like headache, 
cramps, paresthesia were among the complaints in 168 (50.45%). Lower 
urinary tract complaints like dysuria, poor urinary stream, urgency, 
hesitancy were present in 25 (7.5%) and pruritus in 11 (3.3%)  patients, 
while no patient in the study had any bleeding manifestation as the 
presenting complaint. 
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TABLE9. PRESENTING SYMPTOMS 
 
 
PRESENTING 
COMPLAINT 
 
NUMBER 
 
PERCENTAGE 
 
Volume Overload 242 72.67 
 
Oliguria 231 69.36 
 
Dyspnea 252 75.68 
 
GI Symptoms 223 66.97 
 
Neuromuscular 168 50.45 
 
LUTS 25 7.5 
 
Pruritus 11 3.3 
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CURRENT MANAGEMENT  
 
In this study, 182(54.65%) patients were managed conservatively and 
136(40.84%) were given dialysis. Peritoneal dialysis(83.82%) was the most 
common mode of dialysis provided. 
TABLE10. CURRENT MANAGEMENT 
 
 
TREATMENT 
 
NUMBER 
 
PERCENTAGE 
 
Conservative 182 54.65 
 
Dialysis 136 40.84 
 
Transplant 15 4.50 
 
TOTAL 333 100.00 
 
 
 
TABLE11. MODE OF DIALYSIS 
 
 
 
MODE OF DIALYSIS 
 
NUMBER 
 
PERCENTAGE 
 
Peritoneal 114 83.82 
 
Hemodialysis 22 16.17 
 
TOTAL 136 100.00 
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CKD STAGE AT PRESENTATION 
Majority of the patients in the study – 264(79.28%) presented in stage 5 
CKD. The mean GFR in the study population, calculated by MDRD formula, 
was 10.81±6.92. 
TABLE12. CKD STAGE AT PRESENTATION 
 
CKD STAGE 
 
NUMBER 
 
PERCENTAGE 
 
MALE 
 
FEMALE 
 
3 9 2.70 5 4 
 
4 60 18.02 39 21 
 
5 264 79.28 173 91 
 
TOTAL 333 100.00 217 116 
 
 
 
TABLE13. AGEWISE DISTRIBUTION OF CKD STAGE 
 
AGE 
 
STAGE 3 
 
STAGE 4 
 
STAGE 5 
 
≤20yrs 4 4 14 
 
21-40yrs 1 21 95 
 
41-60yrs 3 29 126 
 
>60yrs 1 6 29 
 
TOTAL 9 60 264 
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HEMOGLOBIN IN THE STUDY POPULATION 
               The mean hemoglobin in the study population was 8.42±2.20 g/dl  
varying within a range of 4g/dl to 16.8g/dl. Anemia (hemoglobin less than  
11g/dl) was present in 301 (90.39%) while 85 (25.53%) had hemoglobin less 
than 7g/dl. 
TABLE14. HEMOGLOBIN DISTRIBUTION 
 
 
Hb (g/dl) 
 
NUMBER 
 
PERCENTAGE
 
MALE 
 
FEMALE 
 
>11 32 9.61 24 8 
 
7-11 216 64.86 141 75 
 
<7 85 25.53 52 33 
 
TOTAL 333 100.00 217 116 
 
TABLE15. AGEWISE DISTRIBUTION OF  
HEMOGLOBIN IN CKD 
 
 
AGE GROUP 
 
Hb (g/dl) 
 
≤20yrs 
 
21-40yrs 
 
41-60yrs 
 
>60yrs 
 
TOTAL 
 
>11 3 7 14 8 32 
 
7-11 12 73 114 17 216 
 
      <7 6 38 30 11 85 
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S. PHOSPHATE IN THE STUDY POPULATION  
 
                 Mean S.Phosphate of the study population is 5.94±1.21, varying 
within a range of 2.8 to 11.9. S.Phosphate was less than 4.7mg/dl only in 
12.91%. 
TABLE16. DISTRIBUTION OF S.PHOSPHATE IN THE 
STUDY POPULATION 
 
 
S.PHOS 
(mg/dl) 
 
NUMBER 
 
PERCENTAGE
 
MALE 
 
FEMALE 
 
<4.7 43 12.91 31 12 
 
4.7-6.5 192 57.59 128 64 
 
>6.5 98 29.46 58 40 
 
TOTAL 333 100.00 216 117 
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STAGEWISE DISTRIBUTION OF HEMOGLOBIN LEVELS    
Mean hemoglobin in Stage 3 was 9.167mg/dl, 10.195mg/dl in Stage 4 and 
7.993 mg/dl in Stage 5. Anemia (hemoglobin less than 11g/dl) was present 
in 66.6% in Stage 3, 75% in Stage 4 and 94.7% in Stage 5. 
TABLE17. STAGEWISE DISTRIBUTION OF HEMOGLOBIN 
LEVELS 
  
STAGE 3 
 
STAGE 4 
 
STAGE 5 
 
OVERALL
 
Mean  Hb(g/dl) 
 
9.167 
 
10.195 
 
7.993 
 
8.42 
 
 
Hb(g/dl) 
 
STAGE 3 
 
STAGE 4 
 
STAGE 5 
 
>11 3 (33.3%) 15 (25.0%) 14 (5.3%) 
 
7-11 2 (22.2%) 40 (66.7%) 174 (65.9%) 
 
<7 4 (44.4%) 5 (8.3%) 76 (28.8%) 
 
TOTAL 9 (100%) 60 (100%) 264 (100%) 
                                                                                                    
                                                                                                         p < 0.0005                           
 
Correlation between the hemoglobin level and the CKD stage is highly 
significant. 
Correlation coefficient for Hb and GFR-        0.3657                                                                  
                                                                        p  <0.0005 (highly significant) 
 49
STAGEWISE DISTRIBUTION OF S.PHOSPHATE LEVELS 
Mean S.Phosphate was 4.786% in Stage 3, 5.39 in Stage 4 and 6.1312 in 
Stage 5. In Stage 3, percentage of patients with S.Phosphate more than or 
equal to 4.7mg/dl was 55.5, 66.67% in Stage 4 and 93.55% in Stage 5. 
TABLE18. STAGEWISE DISTRIBUTION OF S.PHOSPHATE 
LEVELS 
 
 
STAGE 3 STAGE 4 STAGE 5 OVERALL
 
Mean S.Phos 
(mg/dl) 
 
4.786 
 
5.39 
 
6.1312 
 
5.94 
 
 
 
S.PHOS (mg/dl) 
 
STAGE 3 
 
STAGE 4 
 
STAGE 5 
 
<4.7 4 (44.4%) 20 (33.33%) 17 (6.44%) 
 
4.7-6.5 5 (55.5%) 27 (45.0%) 160 (60.6%) 
 
>6.5 0 (0%) 13 (21.67%) 87 (32.95%) 
 
TOTAL 9 (100%) 60 (100%) 264 (100%) 
                                                                                     
                                                                                                 p < 0.005 
 
Correlation between S.Phosphorus and CKD stage is highly significant. 
Correlation coefficient for S.Phosphorus and GFR is  -.3580                                                  
                                                                      p <0.0005 (highly significant) 
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TABLE19. CORRELATION OF HEMOGLOBIN LEVELS 
WITH ETIOLOGICAL DIAGNOSIS 
 
 
 
ETIOLOGICAL DIAGNOSIS 
 
Hb 
(g/dl) 
CGN DIAB 
NEPH 
HTN NEPH NON-
GLOMERU
LAR 
UNDETER
-MINED 
 
<7 46(26.9%) 15(20.5% 7(24.8%) 10(11.8%) 7(21.2%) 
 
7-11 112(66.1%) 51(69.9%) 14(53.8%) 17(56.3%) 22(66.7%) 
 
>11 12(7.0%) 7(9.6%) 5(21.4%) 4(12.5%) 4(12.1%) 
 
 TOT 170(100%) 73(100%) 26(100%) 31(100%) 33(100%) 
                                                             
                                                                                                       p = .42666 
 
Correlation between hemoglobin levels and the etiological diagnosis is not  
significant. 
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TABLE20. CORRELATION OF S.PHOSPHATE LEVELS WITH 
ETIOLOGICAL DIAGNOSIS 
 
 
 
ETIOLOGICAL DIAGNOSIS 
 
S.PHO
S 
(mg/dl) 
CGN DIAB 
NEPH 
HTN 
NEPH 
NON-
GLOMERUL
AR 
UNDETER
-MINED 
 
<4.7 27(15.8%) 7(9.6%) 0 5(16.1%) 4(12.1%) 
 
4.7-6.5 91(53.8%) 46(63%) 14(53.8%) 18(58.1%) 22(66.7%) 
 
>6.5 52(30.4%) 
  
20(27.4%) 12(46.2%) 8(25.8%) 7(21.2%) 
 
TOT 170(100%) 73(100%) 26(100%) 31(100%) 33(100%) 
                                                                                p = .44358 
 
Correlation between S.Phosphate levels and the etiological diagnosis is not  
 
significant. 
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TABLE21. CORRELATION BETWEEN THE CKD STAGE AT 
 
PRESENTATION AND THE ETIOLOGICAL 
 
DIAGNOSIS 
 
 
 
 
ETIOLOGICAL DIAGNOSIS 
 
STAGE 
 
CGN 
 
DIAB 
NEPH 
 
HTN 
NEPH 
 
NON-
GLOMERU
LAR 
 
UNDETER
-MINED 
 
 3 4(2.3%) 1(1.4%) 0 3(9.7%) 1(3%) 
 
4 29(17%) 12(16.4%) 3(11.5%) 6(19.4%) 10(30.3%) 
 
 5 137(80.7%) 60(82.2%) 23(88.5%) 22(70.9%) 22(66.7%) 
 
TOT 170(100%) 73(100%) 26(100%) 31(100%) 33(100%) 
                                                                                       
                                                                                                         p = .13855 
 
Correlation between the stage at presentation and the etiological diagnosis is  
 
not significant.  
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CORRELATION BETWEEN CARDIOVASCULAR DISEASE 
AND AGE 
 
Cardiovascular disease in the study population was least in the age group  
 
less than or equal to 20 years (27.3%), while it was present in 56.3% of  
 
patients in the age group 41-60 years. 
 
  
TABLE22. CORRELATION BETWEEN CARDIOVASCULAR  
                    
                   DISEASE AND AGE 
 
 
 
 
AGE GROUP 
 
CVD ≤20yrs 21-40yrs 41-60yrs >60yrs 
 
Yes 6 (27.3%) 53 (45.3%) 89 (56.3%) 19 (52.8%) 
 
No 16 (72.7%) 64 (54.7%) 69 (43.7%) 17 (47.2%) 
 
TOTAL 22 (100%) 117 (100%) 158 (100%) 36(100%) 
                                                                                           
                                                                                                    p = .04169 
 
There is a significant correlation between cardiovascular disease and the age  
 
in the study population. 
 
 
 
 
 
 
 
 54
TABLE23.CORRELATION BETWEEN CARDIOVASCULAR 
 
DISEASE AND THE ETIOLOGICAL DIAGNOSIS 
 
 
 
 
ETIOLOGICAL DIAGNOSIS 
 
CVD 
 
CGN 
 
DIAB 
NEPH 
 
HTN 
NEPH 
 
NON-
GLOMERUL
AR 
 
UNDETER
-MINED 
 
Yes 
 
79 (46.2%) 
 
48(65.8%)
 
22(84.6%)
 
9(29.0%) 
 
9(27.3%) 
 
No 
 
91 (53.8%) 
 
25(34.2%)
 
4(15.3%) 
 
22(71.0%) 
 
24(72.7%) 
 
TOT 
 
170(100%) 
 
73(100%) 
 
26(100%) 
 
31(100%) 
 
33(100%) 
                                                                          
                                                                                         p < .0005 
 
The correlation between cardiovascular disease and the etiological diagnosis 
is highly significant. 
Cardiovascular disease was more common when the cause of CKD was 
Diabetic nephropathy (65.8%) or Hypertensive nephrosclerosis(84.6%). 
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TABLE24. CORRELATION BETWEEN CARDIOVASCULAR 
DISEASE AND DIABETES MELLITUS 
 
 
 DM 
 
CVD Yes No 
 
Yes 49 (61.2%) 118 (46.6%) 
 
No 31 (38.8%) 135 (53.4%) 
 
TOTAL 80 (100%) 253 (100%) 
                                                                            
                                                                                            p = .02273 
 
There is a significant correlation between presence of cardiovascular disease 
and Diabetes mellitus in the study population. 
 
 
 
 
 
 
 
 
 
 
 
 56
TABLE25. CORRELATION BETWEEN CARDIOVASCULAR 
 
DISEASE AND HYPERTENSION 
  
 
 HTN 
 
CVD Yes No 
 
Yes 159 (56.4%) 8 (15.7%) 
 
No 123 (43.6%) 43 (84.3%) 
 
TOTAL 282 (100%) 51 (100%) 
                                                                   
                                                                                p < 0.0005    
 
 
The correlation between presence of cardiovascular disease and 
hypertension is highly significant in the study population. 
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TABLE26. CORRELATION OF CARDIOVASCULAR 
DISEASE AND HEMOGLOBIN LEVELS 
 
 
 
 Hb (g/dl) 
 
CVD <7 7-11 >11 
 
Yes 52 (61.2%) 90 (41.7%) 25 (78.1%) 
 
No 33 (38.8%) 126 (58.3%) 7 (21.9%) 
 
TOTAL 85 (100%) 216 (100%) 32 (100%) 
                                                                                           
                                                                                                p= .00004 
 
 
The correlation between the presence of cardiovascular disease and the 
hemoglobin levels is highly significant in the study population. 
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TABLE27. CORRELATION OF CARDIOVASCULAR 
DISEASE AND S.PHOSPHATE LEVELS 
 
 
 
 S.Phos (mg/dl) 
 
CVD <4.7 4.7-6.5 >6.5 
 
Yes 16 (37.2%) 107 (55.7%) 64 (65.3%) 
 
No 27 (62.7%) 85 (44.3%) 34 (34.7%) 
 
TOTAL 43 (100%) 192 (100%) 98 (100%) 
                                                                   
                                                                                   p = .00225 
 
 
The correlation between the presence of cardiovascular disease and the 
S.Phosphate levels is highly significant in the study population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 59
TABLE28. CORRELATION OF CARDIOVASCULAR 
DISEASE WITH CKD STAGE 
 
 
 
CVD STAGE 3 STAGE 4 STAGE 5 
 
Yes  4 (44.4%) 32 (53.3%) 131 (49.6%) 
 
No 5 (55.6%) 28 (46.7%) 133 (50.4%) 
 
TOTAL 9 (100%) 60 (100%) 264 (100%) 
                       
                                                                                             p = .82286 
 
 
There is no significant correlation between the presence of cardiovascular 
disease and the CKD stage at presentation in the study population.  
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 FIGURE 1. AGE DISTRIBUTION 
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FIGURE 3.  ETIOLOGICAL DIAGNOSIS 
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FIGURE4. DIABETES MELLITUS, HYPERTENSION AND   
                  CARDIOVASCULAR DISEASE IN THE STUDY  
                      POPULATION 
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FIGURE 5. AGEWISE DISTRIBUTION OF DM, HTN & CVD 
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FIGURE 6. FAMILY HISTORY OF DM, HTN, CVD AND  
     CKD IN THE STUDY POPULATION 
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FIGURE 7. HABITS IN THE STUDY POPULATION  
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             FIGURE 8. HEMOGLOBIN DISTRIBUTION  
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FIGURE 9. DISTRIBUTION OF S.PHOSPHATE (mg/dl) 
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FIGURE 10. PRESENTING SYMPTOMS 
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FIGURE 11. CURRENT MANAGEMENT 
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FIGURE 12.MODE OF DIALYSIS 
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FIGURE 13.CKD STAGE (MDRD) AT PRESENTATON 
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 FIGURE 14.STAGEWISE DISTRIBUTION OF CVD 
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FIGURE 15.CKD STAGEWISE MEAN HEMOGLOBIN (g/dl) 
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          FIGURE 16.STAGEWISE HEMOGLOBIN (g/dl)                 
                              DISTRIBUTION 
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FIGURE 17.STAGEWISE MEAN S.PHOSPHATE(mg/dl) 
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          FIGURE 18. STAGEWISE S.PHOSPHATE (mg/dl)  
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 DISCUSSION 
 
               The centre where the study has been conducted is a Government 
setup where a live kidney donor transplant program is functioning and a 
routine maintenance hemodialysis facility is absent. Almost all the patients 
with chronic kidney disease who are admitted are given peritoneal dialysis. 
If the patient is suitable for transplant and live donor is available, he is 
registered under the transplant program and given maintenance hemodialysis 
awaiting transplant. 
 
AGE AND GENDER 
            In our study of 333 patients with CKD, 65.17% were males, which is 
consistent with the CKD Registry of India Report77 where males constituted 
68.9% of the total CKD patients and CMC Vellore Study79 where 62% were 
males, probably reflect the faster decline in GFR in males as compared to 
females due to hormonal influence. Majority of the patients were in the 
group 41-60years, with a mean age of 43.81±14.87 years. The mean age in 
CKD Registry of India Report77 is 48.3±16.6 years and CMC, Vellore 
study79 38.2±14.5 years. 
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EDUCATION AND SOCIOECONOMIC STATUS 
             In our study, out of the 333 patients, 84.38% of the patients were 
illiterate or just had primary education and all the patients were in low 
socioeconomic group with 84.68% having monthly family income < 
Rs.5000. Though relation of low socioeconomic and educational status with  
CKD has already been found in previous related studies, it cannot be 
inferred from our study because we cater to patients with low socioeconomic 
status. 
 
CAUSE 
              Chronic glomerulonephritis was the commonest cause of CKD in 
our study -170 (51.05%) which is consistent with the study done in 
CMC,Vellore79 where CGN was the diagnosis in 70.5% excluding Diabetic 
nephropathy. Diabetic nephropathy (21.92%), Hypertensive nephrosclerosis 
(7.81%) and Tubulointerstitial disease(4.8%) were the other causes of CKD 
in that order, with 9.91% having undetermined etiology. Thus even with the 
epidemic of noncommunicable disease like diabetes and hypertension, and 
increasing incidence of CKD due to these diseases in developing countries, 
chronic glomerulonephritis continues to be the most common cause.  
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DIABETES AND CKD 
             In patients with Diabetes mellitus, 63.75% had a known duration 
less than 10 years and 23.75%, less than 5 years. In the CKD Registry of 
India Report77, 40.7% of diabetics had duration less than 10 years and 16.9% 
less than 5 years. This emphasizes the importance of checking for 
microalbuminuria and proteinuria at the time of diagnosis of type 2 DM.  
 
HYPERTENSION AND CKD 
             While 282 (84.68%) had hypertension, only in 28 (8.41%) was CKD 
due to Hypertensive nephrosclerosis. According to the CKD registry of India 
Report77, 71% had hypertension, while Hypertensive nephrosclerosis was 
the cause of CKD in only 19.8%.  
 
FAMILY HISTORY OF RISK FACTORS 
              Family history of DM (29;8.71%), hypertension (43;12.91%) and 
CKD(4;1.2%) were present only in a small number of patients. 
 
HABITS AND CKD 
             Cigarette smoking was prevalent in 32.73%, alcohol consumption in 
6.91%, use of nephrotoxic agents like NSAIDS in 5.1% and herbominerals 
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in 4.5% which might have contributed to the faster progression of the 
disease in these patients. This is consistent with the CKD Registry of India 
Report77, where cigarette smoking was prevalent in 32%, alcohol 
consumption in 6.4%, NSAIDS use in 2%. 
 
SYMPTOMS 
             Dyspnea was the commonest symptom, observed in 75.68%, 
symptoms of volume overload in 72.67%, oliguria in 69.36%, 
gastrointestinal symptoms in 66.97% and neuromuscular symptoms in 
50.45%. There needs to be a high index of suspicion of CKD even in 
patients presenting with symptoms related to other systems. 
 
CURRENT TREATMENT 
          54.65% of the patients were managed conservatively. 45.34% received 
some form of renal replacement treatment, majority being peritoneal dialysis 
(75.49%). Only 4.5% underwent renal transplantation. These observations in 
our study do not concur with the CKD Registry of India Report77 where 
76.9% of the patients were managed conservatively and among the patients 
on dialysis, maintenance hemodialysis was the preferred mode of 
dialysis(86.59%). Only 2.5% patients received renal transplant. 
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CKD STAGE AT PRESENTATION 
             An overwhelming 264 (79.28%) patients in our study presented for 
the first time with CKD stage 5. Only 18.03% were in stage 4, 2.7% in Stage 
3 and none in Stages 1 or 2, which is consistent with the observations made 
in the CKD Registry of India Report77, where 50.3% presented in Stage 5, 
24% in Stage 4, 19.1% in Stage 3, 4.4% in Stage 2 and 2.2% in Stage 1. This 
reflects the lack of awareness about CKD in the public and the failure of the 
medical practitioners to screen the at risk population and to diagnose CKD at 
an early stage, which would enable appropriate treatment to be instituted to 
prevent or reduce the rate of progression of CKD and bring down the huge 
burden due to mismatch between demand and availability of resources for 
renal replacement therapy in developing countries like India, especially for 
low socioeconomic group. 
 
HEMOGLOBIN 
          The mean hemoglobin level in the study population was 8.42±2.20g/dl. 
301 (90.39%) had anemia (cutoff taken as 11g/dl) , while  25.53% had a 
value less than 7g/dl. Prevalence of anemia increased from Stage 3 (66.6%) 
to stage 5 (94.7%) and the correlation was statistically significant. This is 
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consistent with the CKD Registry of India Report77 where anemia was 
present in 32.6% of Stage 3, 57.5% of Stage 4 and 83.2% of Stage 5 patients.   
 
The mean hemoglobin level was found to increase from stage 3 (9.167) 
to stage 4 (10.195) and then decrease drastically in stage 5 (7.993) probably 
due to less number of patients in stage 3 influencing the mean hemoglobin 
value. These observations do not match with the CKD Registry of India 
Report where mean hemoglobin levels were 10.92g/dl in Stage 3, 9.75g/dl in 
Stage 4 and 8.33g/dl in Stage 5. 
 
S.PHOSPHATE 
                     The mean S.Phosphate level in the study was 5.91±1.21mg/dl. 
Only 43 (12.91%) had S.Phosphate below the recommended value in CKD 
of 4.7mg/dl., while 98 (29.46%) had a value more than 6.5mg/dl. Mean 
S.Phosphate level increased from 4.786mg/dl in stage 3 to 5.39mg/dl in 
stage 4 and 6.1312mg/dl in stage 5, which is consistent with the observations 
in CKD Registry of India Report77 where mean S.Phosphate levels were 
4.54mg/dl in Stage 3, 4.93mg/dl in Stage 4 and 5.91mg/dl in Stage 5.The 
percentage of patients with S.Phosphate more than or equal to 4.7mg/dl 
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increased from 55.5% in stage 3 to 66.67% in stage 4 to 93.55% in stage 5. 
The correlation was found to be statistically significant. 
 
There was no significant correlation between etiological diagnosis and 
hemoglobin levels, S.Phosphate levels or the stage of CKD at presentation. 
 
CARDIOVASCULAR DISEASE 
                 Cardiovascular disease was present in 167 (50.15%) patients, of  
which left ventricular hypertrophy was the commonest (141; 83.93%), while 
in the CKD Registry of India Report77, ischemic heart disease (44.2%) was 
the commonest with left ventricular hypertrophy in 31.6%. Cardiovascular 
disease was more common when the etiological diagnosis was diabetic 
nephropathy (65.8%) or hypertensive nephrosclerosis (85.7%) and the 
correlation was statistically significant. The correlation of cardiovascular 
disease and the presence or absence of DM as well as of hypertension was 
statistically significant. This is consistent with the findings in CKD Registry 
of India.77 
                  
                      Among patients with anemia there was a higher incidence of 
cardiovascular disease in patients with hemoglobin less than 7g/dl (61.2%) 
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than those having value between 7-11g/dl (41.7%) and the correlation was 
statistically significant. But there was a paradoxical increase in percentage of  
patients with cardiovascular disease among those with value more than 
11g/dl (78.1%). Because of the less number of patients in this group, 
whether there is an association between increased risk of cardiovascular 
disease and higher values of hemoglobin above 11g/dl in patients with CKD 
not on dialysis needs further study. Such a relation has been found in 
patients on dialysis given erythropoietin.68  These observations are not 
consistent with those of the study done in tertiary care centre in Chennai,80 
where 82% with hemoglobin less than 7g/dl, 80% with hemoglobin between 
7-11g/dl and 68% with hemoglobin more than 11g/dl had left ventricular 
hypertrophy.  
 
                  Cardiovascular disease was also found to be more frequent when  
S.Phosphate was more than 6.5mg/dl (65.3%) as compared to 4.7-6.5mg/dl 
(55.7%) or less than 4.7mg/dl (37.2%) and the correlation was statistically 
significant. The correlation between cardiovascular disease and CKD stage 
was not statistically significant, probably indicating that risk for 
cardiovascular disease starts in the early stages itself.    
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                     To execute a change in the management of patients with CKD, 
medical students, healthcare professionals, and established physicians, need 
to be educated about the prevalence and consequences of CKD. The concept  
that CKD is a risk factor for cardiovascular disease, and needs to be 
managed should be emphasized. Screening of the high risk individuals 
(those with hypertension, diabetes mellitus, cardiovascular disease and first 
degree relatives of patients with hypertension, diabetes mellitus or renal 
disease) will maximize the detection of CKD and benefit a large population 
of patients.  
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LIMITATIONS 
 
 
1. Most of the patients attending the centre of the study belong to the            
low socioeconomic and educational status and hence are not an               
accurate representation of the general population. 
2. Histopathological diagnosis was lacking for most of the patients as 
they had contracted kidney at presentation, hence diagnosis was     
entirely based on clinical and laboratory criteria. 
3. For 33 patients, the etiology remained undetermined. 
4. Presence of cardiovascular disease was studied based on non invasive 
      tests like ECG and echocardiogram, wherever indicated. Hence the           
         prevalence would have been underestimated.         
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CONCLUSION 
 
 
1. Chronic glomerulonephritis is the commonest cause of Chronic     
kidney disease in the study population. 
2. More than three fourth of patients presented with stage 5 Chronic      
kidney disease for the first time. 
3. Less than half of the patients received renal replacement treatment. 
4. Complications like anemia and hyperphosphatemia increased with     
progression of stage of Chronic kidney disease. 
5. Cardiovascular disease in Chronic kidney disease is more common in      
the presence of  Diabetes mellitus, Hypertension, Hyperphosphatemia. 
6. In patients with anemia, cardiovascular disease was more common      
when hemoglobin levels were less than 7g/dl.  
7. Correlation between cardiovascular disease and stage of Chronic      
kidney disease could not be established in the study.  
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                                     ABBREVIATIONS 
 
 
CKD                         –  Chronic Kidney Disease 
 
ESRD                       – End Stage Renal Disease 
 
GFR                          - Glomerular Filtration Rate 
 
MDRD                     – Modified Diet in Renal Diseases 
 
NKF/KDOQI           – National Kidney Foundation/ Kidney Disease  
 
                                    Outcome Quality Initiative 
 
NHANES             – National Health And Nutritional Examination Survey 
 
NSAID                    – Non Steroidal Anti Inflammatory Drugs 
 
CVD                       – Cardiovascular Disease 
 
LVH                       – Left Ventricular Hypertrophy 
 
IHD                        – Ischemic Heart Disease 
 
CGN                       – Chronic Glomerulonephritis 
 
MHD                      – Maintenance Hemodialysis 
 
CAPD                     – Continous Ambulatory Peritoneal Dialysis 
 
PTH                         - Parathormone 
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PROFORMA 
 
CHRONIC KIDNEY DISEASE 
 
NAME:                                                        NEPHRO. NO: 
AGE:                                                            DATE: 
SEX:                                                            EDUCATION: 
MONTHLY FAMILY INCOME: 
 
HISTORY 
Presenting Complaints 
 
Symptom   Duration Symptom   Duration 
B/l leg swelling   Anorexia   
POF   Nausea   
Oliguria   Vomiting   
Polyuria   Hiccups   
Nocturia   Diarrhea   
Hematuria   Fever   
Dyspnoea   Abd pain   
Chest pain   Loin pain    
Headache   Pain on voiding   
Sleep disturbance   Difficulty in voiding   
Weakness   Urgency    
Numbness   Hesitancy   
Paresthesia   Urinary stream   
Muscle cramps   Skin rash   
Joint pain   Itching   
Bleeding any  site   Deafness   
 
Past History 
 Duration Rx 
HTN   
DM   
IHD   
 
 
 105
 
Family History 
HTN    CKD  
DM  CAD  
 
Drug History 
 Duration  Duration 
ACEI   Alcohol   
NSAIDS  Tobacco  
Native medicine    Other nephrotoxic drugs    
 
 
PHYSICAL EXAMINATION 
 
Consciousness  Pallor  Wt  
Orientation  Icterus  Hydration  
PR  Cyanosis  JVP  
BP  Clubbing    
RR  Lymphnodes  P/ A  
Temp  Tongue  CVS  
Postural fall in BP  Skin turgor     RS  
Stomatitis  Pedal edema     CNS  
Glossitis  Periorbital edema    
            
 
INVESTIGATIONS 
Urine     Hb    
Osmolality    PCV    
Ph    TLC    
Proteins    DLC    
Sugar    ESR    
Cells    PLT    
Casts    B.Urea    
Protein    S.Creat    
Creat    S.Na    
PCR    S.K    
Culture    B.Sugar    
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T.Bil  S.Uric acid  pH  
OT/PT  S.Phosph  pCO2  
S.A.P  S.Ca  HCO3  
T.P/Alb  S.PTH  Cl  
T.Chol      
 
 
ECG 
 
CXR 
 
USG KUB 
 
ECHO 
 
PREVIOUS ADMISSIONS 
 
Diagnosis - 
Treatment given –  
 
CALCULATED GFR  -  CG formula                                  Stage -  
                                         MDRD formula                           Stage -  
 
TREATMENT 
 
Medication                              Dialysis                           Transplant                                            
 
 
 
                       
OUTCOME 
Symptoms controlled with medication alone   (         ) 
Requires dialysis intermittently                       (          ) 
Transplant indicated – donor – available (       )    not available (        )  
Post transplant state   (        )  
Death                         (        )  
Lost for follow up      (        )  
 
 107
PATIENT CONSENT FORM 
 
STUDY TITLE: 
“A STUDY ON CAUSES, CLINICAL & BIOCHEMICAL PROFILE, 
COMPLICATIONS AND OUTCOME IN PATIENTS WITH CHRONIC KIDNEY 
DISEASE IN GGH, CHENNAI” 
 
Study centre            :          Institute of Internal Medicine and Department of  Nephrology                                               
                                           Madras Medical College 
Patient’s Name        :        ________________________________________________ 
Patient’s Age           :        ________________________________________________ 
Identification No.    :        ________________________________________________ 
 
                                                                                          Patient’s may (√ ) these boxes 
 
I confirm that I have understood the purpose of procedure of the above study. I have had the 
opportunity to ask questions and all my questions and doubts have been answered to complete 
satisfaction.       
          
I understand that my participation in the study is voluntary and that I am free to withdraw at any 
time without giving any reason, without my legal rights being affected.  
 
I understand that the sponsor of this clinical study, others working on the sponsor’s behalf, the 
ethics committee and the regulatory authorities will not need my permission to look at my heath 
records both in respect to the current study and any further research that may be conducted in 
relation to it, even if I withdraw from the study. I agree to this access. However, I understand that 
my identity will not be reealed in any information released to third parties, or published, unless as 
required under the law. I agree not to restrict the use of any data or results that arise from this 
study.       
 
I agree to take part in the above study and to comply with instructions given during the study and 
to co-operate with the study team, and to immediately inform the study staff if I suffer from 
any deterioration of health or any unexpected or unusual symptoms.   
 
I hereby consent to participate in this study on “A Study on the Causes, Clinical & 
Biochemical profile, Complications and Outcome in patients with Chronic Kidney 
Disease in GGH, Chennai”. I hereby give permission to undergo complete clinical 
examination, and diagnostic tests.    
 
 
Signature/Thumb impression ________________  Place___________ Date________ 
  of the patient 
 
Patient’s Name and Address _____________________________________________ 
 
                                                ____________________________________________  
 
Signature of the Investigator _________________ Place_________  Date_________ 
 
Study Investigator’s Name  _______________________________ 
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